全文获取类型
收费全文 | 117533篇 |
免费 | 10741篇 |
国内免费 | 292篇 |
专业分类
耳鼻咽喉 | 1593篇 |
儿科学 | 3387篇 |
妇产科学 | 2376篇 |
基础医学 | 16157篇 |
口腔科学 | 2657篇 |
临床医学 | 13435篇 |
内科学 | 22951篇 |
皮肤病学 | 1842篇 |
神经病学 | 9875篇 |
特种医学 | 3919篇 |
外国民族医学 | 11篇 |
外科学 | 16364篇 |
综合类 | 2100篇 |
一般理论 | 84篇 |
预防医学 | 12289篇 |
眼科学 | 2626篇 |
药学 | 9320篇 |
2篇 | |
中国医学 | 138篇 |
肿瘤学 | 7440篇 |
出版年
2021年 | 1715篇 |
2020年 | 1109篇 |
2019年 | 1719篇 |
2018年 | 2108篇 |
2017年 | 1537篇 |
2016年 | 1669篇 |
2015年 | 1879篇 |
2014年 | 2650篇 |
2013年 | 4044篇 |
2012年 | 5723篇 |
2011年 | 6065篇 |
2010年 | 3267篇 |
2009年 | 3070篇 |
2008年 | 5447篇 |
2007年 | 5979篇 |
2006年 | 5927篇 |
2005年 | 5911篇 |
2004年 | 5632篇 |
2003年 | 5326篇 |
2002年 | 5186篇 |
2001年 | 2971篇 |
2000年 | 3013篇 |
1999年 | 2817篇 |
1998年 | 1543篇 |
1997年 | 1244篇 |
1996年 | 1219篇 |
1995年 | 1122篇 |
1994年 | 1111篇 |
1993年 | 1007篇 |
1992年 | 2304篇 |
1991年 | 2180篇 |
1990年 | 2053篇 |
1989年 | 2002篇 |
1988年 | 1914篇 |
1987年 | 1938篇 |
1986年 | 1819篇 |
1985年 | 1827篇 |
1984年 | 1648篇 |
1983年 | 1494篇 |
1982年 | 1170篇 |
1981年 | 993篇 |
1980年 | 884篇 |
1979年 | 1328篇 |
1978年 | 1031篇 |
1977年 | 913篇 |
1976年 | 858篇 |
1975年 | 817篇 |
1974年 | 952篇 |
1973年 | 828篇 |
1972年 | 793篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Isolated patellofemoral arthritis is an increasingly recognized entity, and is usually associated with previous patellofemoral dysplasia or instability. Patellofemoral arthroplasty (PFA) has evolved significantly in recent years, both in terms of implant design and importantly in the understanding of appropriate patient selection. This review outlines the indications and investigations for PFA, provides a brief history of the development of contemporary implants, and presents the clinical outcomes for the prostheses most commonly used in the UK. In addition, it provides a detailed surgical technique for implantation of an onlay implant, with tips on how to optimize patellofemoral biomechanics and thus achieve a consistently good outcome. 相似文献
2.
3.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
4.
5.
6.
James Milligan Joseph Lee Matt Smith Lindsay Donaldson Peter Athanasopoulos Kent Bassett-Spiers 《The journal of spinal cord medicine》2020,43(2):223-233
Context: Persons with spinal cord injury (SCI) experience significant challenges when they access primary care and community services.Design: A provincial summit was held to direct research, education, and innovation for primary and community care for SCI.Setting: Toronto, Ontario, Canada.Participants: Key stakeholders (N?=?95) including persons with SCI and caregivers, clinicians from primary care, rehabilitation, and specialized care, researchers, advocacy groups, and policy makers.Methods: A one-day facilitated meeting that included guest speakers, panel discussions and small group discussions was held to generate potential solutions to current issues related to SCI care and to foster collaborative relationships to advance care for SCI. Perspectives on SCI management were shared by primary care, neurosurgery, rehabilitation, and members of the SCI communityOutcome Measures: Discussions were focused on five domains: knowledge translation and dissemination, application of best practices, communication, research, and patient service accessibility.Results: Summit participants identified issues and prioritized solutions to improve primary and community care including the creation of a network of key stakeholders to enable knowledge creation and dissemination; an online repository of SCI resources, integrated health records, and a clinical network for SCI care; development and implementation of strategies to improve care transitions across sectors; implementation of effective care models and improved access to services; and utilization of empowerment frameworks to support self-management.Conclusions: This summit identified priorities for further collaborative efforts to advance SCI primary and community care and will inform the development of a provincial SCI strategy aimed at improving the system of care for SCI. 相似文献
7.
8.
9.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献
10.